Indications and criteria to start on tonoferon in paediatric age group

Indications and criteria to start on tonoferon in paediatric age groups. Its contraindications

Reading File

Finding Sources

Searching the Web

Tonoferon ferric hydroxide polymaltose indications criteria paediatric contraindications

Finding Sources

Searching the Web

Tonoferon iron polymaltose paediatric dosing criteria haemoglobin ferritin indications

Finding Sources

Reading Web Page

Tonoferon iron polymaltose indications criteria paediatric contraindications dosing

Here is a comprehensive overview of Tonoferon (Ferric Hydroxide Polymaltose Complex, FPC) in the paediatric age group.

What is Tonoferon?

Tonoferon is a brand name for ferric hydroxide polymaltose complex (FPC) - a trivalent (Fe³+) iron preparation. It is available as a syrup (50 mg Fe³+/5 mL) for younger children and chewable/film-coated tablets (100 mg Fe³+) for older children and adolescents. Unlike ferrous salts, it releases iron slowly and does not cause free radical damage, making it generally better tolerated.

Indications in Paediatric Age Groups

1. Treatment of Iron Deficiency Anaemia (IDA)

The primary indication. Iron therapy should be started when both the clinical picture and laboratory criteria are met:

Laboratory diagnostic criteria for IDA (WHO/AAP thresholds):

Age Group	Hb threshold for Anaemia
6 months - 59 months	< 11.0 g/dL
5 - 11 years	< 11.5 g/dL
12 - 14 years	< 12.0 g/dL
Males ≥ 15 years	< 13.0 g/dL
Females ≥ 15 years	< 12.0 g/dL

Supportive lab findings for iron-deficiency origin:

Low serum ferritin (SF) below age-adjusted lower limit - note: with concurrent inflammation, raise the threshold to ≥ 30 µg/L in children < 5 years and ≥ 70 µg/L in children > 5 years
Microcytic, hypochromic picture on CBC (low MCV, MCH)
Low serum iron, raised TIBC, low transferrin saturation (< 16%)
Low reticulocyte haemoglobin concentration (CHr) - considered the strongest single predictor of iron deficiency in children

2. Treatment of Iron Deficiency Without Overt Anaemia

When ferritin is low and/or symptoms of iron deficiency are present (fatigue, poor concentration, ADHD-like behaviour, pica, reduced immunity, breath-holding spells, developmental delay) even with Hb still above the anaemia threshold.

3. Prevention of Iron Deficiency (Prophylactic Use)

Exclusively breastfed infants aged 4-12 months with delayed introduction of iron-rich solids: 1 mg/kg/day elemental iron
Children > 12 months with poor or restricted diet, malabsorptive states: 1-2 mg/kg/day (max 30 mg/day)
Premature/low-birth-weight infants: iron stores are depleted earlier; prophylaxis typically begins at 2-4 weeks of age (dosed per neonatology protocol)

4. High-Risk Groups Where Tonoferon is Specifically Indicated

Toddlers with predominantly cow's milk diet (cow's milk inhibits iron absorption)
Children with chronic blood loss (e.g., hookworm, Meckel's diverticulum, IBD)
Malabsorption syndromes (celiac disease, post-surgical short gut)
Children receiving erythropoiesis-stimulating agents (ESA therapy in CKD)
Vegetarian/vegan children with low dietary iron bioavailability

Criteria to Start Tonoferon (Decision Framework)

Start treatment when ALL of the following are present:

Hb below age-specific threshold (see table above) AND iron studies confirm iron-deficiency aetiology (low ferritin ± low transferrin saturation)
Other causes of anaemia have been excluded or considered (thalassaemia trait, haemolytic anaemia, vitamin B12/folate deficiency)
Oral iron therapy is feasible (no severe malabsorption, no need for urgent IV correction)

Fe³+ polymaltose (Tonoferon) is preferred over Fe²+ salts when:

GI side effects with ferrous salts are a concern
Better palatability/compliance is needed (no metallic taste, dark teeth staining)
Accidental overdose safety is preferred (FPC has a much wider therapeutic window)

Dosing (elemental iron as Fe³+ polymaltose):

Treatment: 3-6 mg/kg/day (max 200 mg/day elemental iron) for at least 3 months
Given with meals (polymaltose requires gastric acid dissolution; can be mixed with juice)
Once normal Hb is achieved, halve the dose and continue for at least 3 more months to replenish stores
Fe²+ salts dose equivalent: 2-3 mg/kg/day given before meals

Monitoring response:

Mild anaemia: repeat CBC at 1 month
Severe anaemia: check reticulocyte count at 7-10 days; expect Hb rise of ≥ 2 g/dL in the first month
Confirm diagnosis is correct if no response at 1 month

Contraindications

Contraindication	Details
Iron overload	Haemochromatosis, haemosiderosis, or any state where iron stores are already elevated (ferritin elevated without inflammation)
Iron utilisation disorders	Anaemia not caused by iron deficiency - e.g., sideroblastic anaemia, lead poisoning, chronic disease anaemia, thalassaemia (major)
Non-iron-deficiency anaemia	Should not be used to treat anaemia that is NOT due to iron deficiency
Concurrent parenteral iron	Must not be given simultaneously with IV/IM iron preparations (risk of iron toxicity)
Hypersensitivity	Known allergy/intolerance to ferric hydroxide polymaltose or any excipient in the formulation
Active infection (relative)	Iron can promote bacterial growth; caution during acute systemic infections, especially malaria or tuberculosis (iron supplementation may reactivate latent TB/malaria)

Key Points on Safety & Tolerability

FPC (Tonoferon) has a significantly lower risk of GI side effects compared to ferrous sulphate - making it preferred in young children
No known food/drug interactions (unlike ferrous salts, which interact with antacids, calcium, tetracyclines)
Accidental ingestion is far safer than ferrous salts - the polymaltose complex limits uncontrolled iron release
Black/dark stools are not expected with FPC (unlike ferrous salts) - absence of dark stools does not indicate non-compliance
Response should be confirmed at 1 month - failure to respond suggests wrong diagnosis, poor compliance, ongoing blood loss, or malabsorption

Sources: WHO Haemoglobin Thresholds for Anaemia; Polish Pediatric Society IDA Guidelines (PMC11547346); Iron Deficiency Anaemia in Infancy, Childhood and Adolescence (PMC10440944); Perth Children's Hospital Iron Monograph; Iron Polymaltose - Wikipedia/Pharmacology data.

This is a shared conversation. Sign in to Orris to start your own chat.